Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine

Transplant International

Volumn 20, Issue 10, 2007, Pages 875-883

  Russ, Graeme ^a   Jamieson, Neville ^b   Oberbauer, Rainer ^c   Arias, Manuel ^d   Murgia, Maria G ^e   Blancho, Gilles ^f   Sato, Reiko ^g   Stoeckl, Maria ^h   Revicki, Dennis A ^h  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e San Michele Hospital   (Italy)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g PFIZER INC   (United States)

^h UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Cyclosporine; Health related quality of life; Immunosuppressive therapy; Kidney Transplant Questionnaire; Kidney transplantation; Randomized clinical trial; Sirolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; RAPAMYCIN;

ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELIMINATION; EMOTION; FATIGUE; HEALTH STATUS; HEALTH SURVEY; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548596623     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00547.x     Document Type: Article

References (33)

1. Humar A, Denny R, Matas AJ, Najarian JS. Graft and quality of life outcomes in older recipients of a kidney transplant. Exp Clin Transplant 2003 1: 69.
2. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003 76: 1699.
3. Shield CF III., McGrath MM, Goss TF. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. Transplantation 1997 64: 1738.
4. Dew MA, Switzer GE, Goycoolea JM, et al. Does transplantation produce quality of life benefits? A quantitative analysis of the literature 3. Transplantation 1997 64: 1261.
5. Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F. Changes in quality of life after renal transplantation. Am J Kidney Dis 1998 32: 93.
6. Keown P. Improving quality of life - the new target for transplantation. Transplantation 2001 12 (Suppl. S67.
7. U.S. Department of Health and Human Services 2004. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1995-2002. Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2004. Available at: http://www.unos.org/data/. Accessed on 25 November, 2005.
8. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4: 378.
9. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001 71: 1282.
10. Flechner SM. Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc 2003 3 (Suppl. 118S.
11. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005 5: 2531.
12. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy following early cyclosporine withdrawal. J Am Soc Nephrol 2004 15: 809.
13. Morales JM, Wramner L, Kreis H, et al. Sirolimous does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002 2: 436.
14. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004 4: 1776.
15. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005 18: 22.
16. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004 4: 953.
17. Campistol JM, Eris J, Oberbauer R, et al. The Rapamune Maintenance Regimen (RMR) Study Group. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006 17: 581.
18. Oberbauer R, Hutchison B, Eris J, et al. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial. Transplantation 2003 75: 1277.
19. Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Car 2000 38 (Suppl II. II14.
20. Laupacis A, Pus N, Muirhead N, Wong C, Ferguson B, Keown P. Disease-specific questionnaire for patients with a renal transplant. Nephron 1993 64: 226.
21. Fiebiger W, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. Health Qual Life Outcomes 2004 2: 2.
22. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
23. Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB. The SF-36 as an outcome measure of services for end stage renal failure. Qual Health Care 1998 7: 209.
24. Verbeke G, Molenberghs G, eds. Linear Mixed Models in Practice: A SAS-Oriented Approach. New York: Springer, 1997.
25. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC, 2002.
26. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998 316: 1236.
27. Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Interpretation. New York: John Wiley & Sons, 2000.
28. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001 72: 777.
29. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002 77: 371.
30. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996 50: 235.
31. Edgell E, Coons S, Carter WB, et al. A review of health-related quality-of-life measures used in end-stage renal disease. Clin Ther 1996 18: 887.
32. Reimer J, Franke GH, Philipp T, Heemann U. Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion. Clin Transplant 2002 16: 48.
33. Kirk AD, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005 18: 2.